Alain Mange

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3145639/publications.pdf

Version: 2024-02-01

63	2,836	136950	175258
papers	citations	32	52
		h-index	g-index

74	74	74	3827
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prion infection impairs the cellular response to oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13937-13942.	7.1	203
2	Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Molecular and Cellular Neurosciences, 2003, 22, 227-233.	2.2	164
3	Cleavage of the Amino Terminus of the Prion Protein by Reactive Oxygen Species. Journal of Biological Chemistry, 2001, 276, 2286-2291.	3.4	154
4	Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein. Biology of the Cell, 2004, 96, 125-132.	2.0	150
5	Proteomics-Based Identification of HSP60 as a Tumor-Associated Antigen in Early Stage Breast Cancer and Ductal Carcinoma in situ. Journal of Proteome Research, 2008, 7, 3830-3837.	3.7	115
6	Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures. Journal of Virology, 2000, 74, 3135-3140.	3.4	112
7	Autoantibody signatures: progress and perspectives for early cancer detection. Journal of Cellular and Molecular Medicine, 2011, 15, 2013-2024.	3.6	100
8	Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women. Clinical Cancer Research, 2009, 15, 4733-4741.	7.0	99
9	Stimulation of PrPC Retrograde Transport toward the Endoplasmic Reticulum Increases Accumulation of PrPSc in Prion-infected Cells. Journal of Biological Chemistry, 2002, 277, 38972-38977.	3.4	98
10	PrP-dependent cell adhesion in N2a neuroblastoma cells. FEBS Letters, 2002, 514, 159-162.	2.8	81
11	Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin. Journal of Cell Science, 2004, 117, 2411-2416.	2.0	78
12	HDL Proteome in Hemodialysis Patients: A Quantitative Nanoflow Liquid Chromatography-Tandem Mass Spectrometry Approach. PLoS ONE, 2012, 7, e34107.	2.5	67
13	Prion Infection Impairs Copper Binding of Cultured Cells. Journal of Biological Chemistry, 2003, 278, 14595-14598.	3.4	54
14	KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues. International Journal of Molecular Sciences, 2011, 12, 3191-3204.	4.1	52
15	FKBP family proteins as promising new biomarkers for cancer. Current Opinion in Pharmacology, 2011, 11, 320-325.	3.5	50
16	D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nature Communications, 2016, 7, 10353.	12.8	50
17	Liquid Chromatography-Tandem and MALDI Imaging Mass Spectrometry Analyses of RCL2/CS100-Fixed, Paraffin-Embedded Tissues: Proteomics Evaluation of an Alternate Fixative for Biomarker Discovery. Journal of Proteome Research, 2009, 8, 5619-5628.	3.7	49
18	Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Review of Proteomics, 2013, 10, 33-42.	3.0	48

#	Article	IF	Citations
19	Comprehensive proteomic analysis of the human milk proteome: Contribution of protein fractionation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 876, 252-256.	2.3	46
20	Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Analytical Biochemistry, 2005, 338, 26-31.	2.4	45
21	Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Review of Proteomics, 2006, 3, 311-320.	3.0	43
22	FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer. Theranostics, 2019, 9, 7003-7015.	10.0	43
23	A strong inhibitory element down-regulates SRE-stimulated transcription of the A3 cytoplasmic actin gene of Bombyx mori. Journal of Molecular Biology, 1997, 265, 266-274.	4.2	42
24	A Naturally Occurring Sequence Variation That Creates a YY1 Element Is Associated with Increased Cystic Fibrosis Transmembrane Conductance Regulator Gene Expression. Journal of Biological Chemistry, 2000, 275, 3561-3567.	3.4	42
25	Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: Application to the sensitive and specific detection of tumor markers from breast cancer sera. Biosensors and Bioelectronics, 2013, 40, 385-392.	10.1	41
26	Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative earlyâ€stage breast cancers. International Journal of Cancer, 2013, 132, 1105-1113.	5.1	41
27	Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids. Proteome Science, 2008, 6, 1.	1.7	39
28	Proteomic analysis of RCL2 paraffinâ€embedded tissues. Journal of Cellular and Molecular Medicine, 2008, 12, 2027-2036.	3.6	38
29	Use of Autoantibodies to Detect the Onset of Breast Cancer. Journal of Immunology Research, 2014, 2014, 1-8.	2.2	38
30	Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer. Clinical Cancer Research, 2012, 18, 1992-2000.	7.0	36
31	Effect of Congo Red on Wild-Type and Mutated Prion Proteins in Cultured Cells. Journal of Neurochemistry, 2001, 74, 222-230.	3.9	35
32	Bombyx gene promoter analysis in transplanted silk gland transformed by particle delivery system. Insect Molecular Biology, 1994, 3, 261-265.	2.0	33
33	EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. International Journal of Molecular Sciences, 2013, 14, 5170-5181.	4.1	32
34	Clinical Relevance of Autoantibody Detection in Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 955-962.	1.1	30
35	Two alternative promoters drive the expression of the cytoplasmic actin A4 gene of Bombyx mori. Gene, 1996, 183, 191-199.	2.2	28
36	Cell Culture Models of Transmissible Spongiform Encephalopathies. Biochemical and Biophysical Research Communications, 2001, 289, 311-316.	2.1	28

#	Article	IF	Citations
37	Humoral response to cancer as a tool for biomarker discovery. Journal of Proteomics, 2009, 72, 982-988.	2.4	28
38	Identifying autoantibody signatures in cancer: a promising challenge. Expert Review of Proteomics, 2009, 6, 377-386.	3.0	28
39	Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes. Journal of Thoracic Oncology, 2008, 3, 840-850.	1.1	26
40	Effect of Amphotericin B on Wild-Type and Mutated Prion Proteins in Cultured Cells. Journal of Neurochemistry, 2001, 74, 754-762.	3.9	25
41	Serum protein signature may improve detection of ductal carcinoma in situ of the breast. Oncogene, 2010, 29, 550-560.	5.9	24
42	Pemphigus vulgaris antigen mRNA quantification for the staging of sentinel lymph nodes in head and neck cancer. British Journal of Cancer, 2010, 102, 181-187.	6.4	24
43	Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells. Biochemical and Biophysical Research Communications, 2008, 375, 107-112.	2.1	23
44	An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. Journal of Proteomics, 2016, 142, 114-121.	2.4	22
45	A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1834-1842.	2.5	21
46	Comparative evaluation of the new FDA approved THxIDâ„¢-BRAF test with high resolution melting and sanger sequencing. BMC Cancer, 2014, 14, 519.	2.6	20
47	Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy. Critical Reviews in Oncology/Hematology, 2015, 93, 312-319.	4.4	20
48	Trafficking of the cellular isoform of the prion protein. Biomedicine and Pharmacotherapy, 1999, 53, 39-46.	5.6	19
49	Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis. Cells, 2019, 8, 1521.	4.1	18
50	Highly sensitive detection of melanoma based on serum proteomic profiling. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1257-1264.	2.5	17
51	Dzip1 and Fam92 form a ciliary transition zone complex with cell type specific roles in Drosophila. ELife, 2019, 8, .	6.0	17
52	Anti-heat shock protein autoantibody profiling in breast cancer using customized protein microarray. Analytical and Bioanalytical Chemistry, 2016, 408, 1497-1506.	3.7	12
53	Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer. Clinical Chemistry and Laboratory Medicine, 2018, 56, e243-e246.	2.3	9
54	Elevated Concentrations of Milk Î²2-Microglobulin Are Associated with Increased Risk of Breastfeeding Transmission of HIV-1 (Vertical Transmission Study). Journal of Proteome Research, 2013, 12, 5616-5625.	3.7	8

#	Article	IF	Citations
55	Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. Radiation Oncology, 2019, 14, 142.	2.7	8
56	Protein interactions study through proximity-labeling. Expert Review of Proteomics, 2019, 16, 717-726.	3.0	7
57	Comparison of Supervised Classification Methods for Protein Profiling in Cancer Diagnosis. Cancer Informatics, 2007, 3, 117693510700300.	1.9	6
58	Proximal Protein Interaction Landscape of RAS Paralogs. Cancers, 2020, 12, 3326.	3.7	6
59	HP1s modulate the S-Adenosyl Methionine synthesis pathway in liver cancer cells. Biochemical Journal, 2020, 477, 1033-1047.	3.7	5
60	Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Informatics, 2007, 3, 295-305.	1.9	5
61	Identification of serum melanoma progression biomarkers through proteomic-based approaches. Expert Review of Proteomics, 2009, 6, 341-343.	3.0	2
62	Nouveaux aspects de la biologie de la protÃ©ine prion. Medecine/Sciences, 2002, 18, 1267-1275.	0.2	0
63	La rÃ©sistance aux inhibiteurs de BRAF. Medecine/Sciences, 2022, 38, 570-578.	0.2	0